2025.11.06
On November 6, 2025, Vigonvita Life Sciences (Vigonvita, stock code: 2630.HK) globally issued 17,597,800 H shares and listed on the Main Board of the Hong Kong Stock Exchange. The issuance price was HKD 33.37 per share, raising over HKD 580 million (before exercising the over-allotment option).
Founded in 2013, Vigonvita is a biopharmaceutical company dedicated to discovering, acquiring, developing and commercializing small molecule drugs used in neuropsychiatric, reproductive health and viral infection treatments. The products acquired and developed by the company include LV232, TPN171 and VV116. LV232 is a dual-target serotonin transporter/serotonin 3 receptor modulator for the treatment of major depressive disorders and TPN171 is an inhibitor for the treatment of erectile dysfunction. VV116 is an RdRp inhibitor that has been approved in China and Uzbekistan for the treatment of COVID-19, under the trade names Mindway® and MINDVY®, respectively, and has completed Phase II clinical development for RSV infection treatment in China. The company has other drug candidates in clinical and preclinical stages.
The JunHe team acted as the domestic legal counsel for the issuer in this project. They conducted domestic legal due diligence, reviewed the listing-related application and issuance documents, issued Chinese legal opinions, assisted the issuer in communicating with the China Securities Regulatory Commission (CSRC), and coordinated responses to questions raised by the CSRC and HKEX regarding domestic legal matters. JunHe also provided legal services related to data compliance for the issuer in this project. JunHe's rigorous, meticulous and comprehensive legal services have earned high praise and recognition from Vigonvita and other intermediary institutions.
The lead partner for this project was TAO, Xudong and SHANG, Shiming (George) was the internal partner. Partner GU, Yu provided significant support to the project.
